Semnur Pharmaceuticals, Inc. · OTC:SMNR
Semnur Pharmaceuticals — Investor Presentation (August 2024)
25 slides from Semnur Pharmaceuticals's investor presentation, August 2024
Slide 1: Getting Back to Normal – Corporate Presentation
Getting Back to Normal Corporate Presentation Wholly Owned Subsidiary of Scilex Holding Company (NASDAQ: SCLX)
Slide 2: Safe Harbor Statements Forward-Looking Statements
Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, “Scilex”) orally in presenting this material, a
Slide 3: History of Semnur Pharmaceuticals
History of Semnur Pharmaceuticals • Semnur founded in 2013 with Series A $30MM 1 investment from Canaan Partners, Frazier Healthcare, and Vivo Capital. • On March 22, 2019, Scilex Pharmaceuticals Inc. has closed a transaction to merge with Semnur Pharmaceuticals, Inc. to form a new company, Scilex H
Slide 4: Semnur Pharmaceuticals Merger with Denali Acquisition Corporation
Semnur Pharmaceuticals Merger with Denali Acquisition Corporation • Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX), and Denali 1 Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination. • On July 2,
Slide 5: SEMDEXA (SP-102) On-Track to be the First Product Approved to Treat Sciatica
SEMDEXA (SP-102) On-Track to be the First Product Approved to Treat Sciatica SP-102 is a preservative free, surfactant free and particulate free viscous gel formulation of dexamethasone for sciatica (lumbosacral radicular pain). Extended local effect provides durable pain relief and significant impr
Slide 6: SP-102 Market Opportunity
SP-102 Market Opportunity Developing SP-102 as a non-opioid injectable therapeutic for low back pain Novel viscous gel formulation, optimized for epidural injection Novel biocompatible excipient enables extended local effect On track to be the first and only FDA-approved epidural steroid product Cur
Slide 7: Differentiated Product Profile & Positioning
SP-102 Differentiated Product Profile & Positioning Depo-Medrol Dexameth- Kenalog Celestone Important Treatment Attributes SP-102 (triamcinolone) (methylprednis- asone (betamethasone) 1 olone) FDA-approved for lumbosacral ✓ – – – – radicular pain Robust clinical data demonstrating safety – ✓ – – – a
Slide 8: Reimbursement – J code Timelines for New Products
SP-102 Reimbursement – J code Timelines for New Products • SP-102 has strong value proposition as the first proven and indicated preservative-free epidural injection for lumbar radiculopathy • Strong case for economic benefits associated with use of epidural steroid injections to defer more complica
Slide 9: Epidural Steroid Injections (ESI) for Chronic Back Pain
Epidural Steroid Injections (ESI) for Chronic Back Pain One of the Most Common Medical Procedures / Top Pain Procedures Strong Growth Rate, Evidenced by Medicare Procedure Volumes (MM) Medicare Overall ESI Injection Volume1 1▪ ESIs widely reimbursed as procedure to delay or avoid back surgery 2▪ Tra
Slide 10: SEMDEXA – Broad Potential for Life Cycle Management
SEMDEXA – Broad Potential for Life Cycle Management 1 Physicians indicated there is potential opportunity for spontaneous use of SEMDEXA outside of lumbar radiculopathy which could represent an additional upside of ~50-200%* over LR 2 Additional Uses ▪ Carpel Tunnel ▪ Hip and Knee Replacements ▪ Tri
Slide 11: Lumbosacral Radicular Pain (Sciatica)
Lumbosacral Radicular Pain (Sciatica) Lifetime incidence 13 - 40% Rarely diagnosed before the age of 20, peaks in the 50s and declines thereafter ~ 90% of cases caused by a herniated disc with nerve root compression Confidential, not for distribution 11
Slide 12: Summary of Select Systematic Reviews and Meta-analyses
Summary of Select Systematic Reviews and Meta-analyses: Meta-Analyses and Systemic Reviews Type Publication Intervention Outcomes Improvement Improvement Surgery in Pain in Function Avoidance RCT Carette 1997 ESI vs Placebo Meta-analysis Chou 2015 ESI Meta-analysis Bhatia 2016 ESI +/- Local Anesthet
Slide 13: Fungal Meningitis Outbreaks
Fungal Meningitis Outbreaks Meningitis outbreak caused by compound pharmacy produced steroids for epidural injections, contaminated with Aspergillus fumigatus, infected more than 800 people across 20 states in 2012, 64 of whom died. By Kurt Eichenwald / April 16, 2015 http://www.newsweek.com/2015/04
Slide 14: History of Serious Spinal Adverse Events Associated with ESIs
History of Serious Spinal Adverse Events Associated with ESIs: Resulting FDA Warning in All Injectable Corticosteroid Product Labels 1997-2014 90 serious (including fatal) neurological events following ESIs reported to FAERS 2014 FDA required warning for all injectable corticosteroid product labels
Slide 15: SP-102 (SEMDEXA) Toxicology GLP Studies (dogs and pigs)
SP-102 (SEMDEXA) Toxicology GLP Studies (dogs and pigs) No drug-related effects on any parameter: ECG, Clin obs, BW, Neurology, Clinical pathology & chemistry. Histopathology: no drug-induced adverse effects, including special stains Dose dependent PK, both plasma & CSF, cleared by 24 h. Cortisol su
Slide 16: SP-102 (SEMDEXA) Pharmacokinetic Bridging Trial
SP-102 (SEMDEXA) Pharmacokinetic Bridging Trial Epidural SP-102 injection was well tolerated Not associated with greater systemic dexamethasone exposure than IV dexamethasone at the same dose 10 mg (Reference Listed Drug) Equivalent AUC Lower mean plasma Cmax (~ 50% lower) Both treatments had simila
Slide 17: SP-102 (SEMDEXA) Phase 2: Repeat Dose PD trial
SP-102 (SEMDEXA) Phase 2: Repeat Dose PD trial The repeat injection had similar effects on cortisol suppression time (~5 days), glucose levels and WBC count. No cumulative effect. There were no SAEs or discontinuations due to adverse events. SP-102 provided prolonged pain relief, with preliminary ev
Slide 18: SP-102 (SEMDEXA) C.L.E.A.R. Trial Schema
SP-102 (SEMDEXA) C.L.E.A.R. Trial Schema Inclusion Radicular leg pain episode (4-9 NPRS) MRI confirmed No prior ESI (epidural steroid injection) No opioids or NSAIDs Stable, >4 avg NPRS pain in 21d screening Primary Endpoint Secondaries (W2, W4, W8, W12) Change in mean leg pain Leg pain (NPRS, avg &
Slide 19: C.L.E.A.R. Trial Met Primary Endpoint
SP-102 (SEMDEXA) C.L.E.A.R. Trial Met Primary Endpoint (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) Primary Endpoint (mITT) Largest prospective, double-blind, randomized study in Sciatica (n=401) Change in Average Daily Pain in Affected Leg 0,5 The trial met primary, key secondary and
Slide 20: C.L.E.A.R. Trial Secondary Endpoints (ITT)
SP-102 (SEMDEXA) C.L.E.A.R. Trial Secondary Endpoints (ITT) Key Secondary Endpoint The Oswestry Disability Index (ODI) - gold standard for measuring degree of disability and estimating quality of life, contains 10 topics concerning intensity of pain, lifting, ability to care for oneself, ability to
Slide 21: C.L.E.A.R. Trial – Effect Duration and Safety
SP-102 (SEMDEXA) C.L.E.A.R. Trial – Effect Duration and Safety SP-102 Time to Repeat Injection (Return of Moderate-Severe Pain) Month 1 Month 2 Month 3 Month 4 Month 5 Primary Endpoint Allowance for Open-Label Repeat Injection of SP-102 SP-102 showed continued reduction of pain beyond one month, and
Slide 22: C.L.E.A.R. Safety Summary
SP-102 (SEMDEXA) C.L.E.A.R. Safety Summary No AEs of special interest (paraplegia, hematoma, infection) No SAEs related to drug or injection procedure No meaningful differences in physical examinations, vital signs, or laboratory parameters between treatment groups Confidential, not for distribution
Slide 23: SP-102 Regulatory Discussion(s) to Date
SP-102 Regulatory Discussion(s) to Date 1 Toxicology program complete 2 Pharmacokinetic bridge established to Reference Listed Drug 3 Phase II, additional PK / PD / Safety of repeat injection trial completed 4 CLEAR Trial completed 5 NDA 505(b)(2) application confirmed 6 23
Slide 24: SP-102 Milestones
SP-102 Milestones 1 CLEAR-2 trial from Q4-2024 to Q3-2026 • CLEAR-2 Trial: Randomized, Active-controlled, Double-Blind, Multi-Center Trial in Subjects with Lumbosacral Radicular Pain (Sciatica). o Endpoints: Non-Inferiority on leg pain over 4 weeks, Superiority on time to repeat injection, treatment
Slide 25: Semnur Pharmaceuticals Management Team
Semnur Pharmaceuticals Management Team Jaisim Shah Suketu Desai Dmitri Lissin, MD Henry Ji, PhD Chief Technology Officer Stephen Ma Chief Executive & President Chief Medical Officer Executive Chairman Chief Financial Officer ▪ 25+ years of management ▪ 25+ years in manufacturing / CMC, ▪ 20+ years i
Semnur Pharmaceuticals — Investor Presentation (August 2024) on 6ix